Trial Profile
A randomized, placebo-controlled, double-blind, multicenter study investigating basiliximab in combination with MMF, cyclosporin microemulsion and prednisone in the prevention of acute rejection in pediatric renal allograft recipients
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 15 Sep 2010
Price :
$35
*
At a glance
- Drugs Basiliximab (Primary) ; Ciclosporin; Mycophenolate mofetil
- Indications Renal transplant rejection
- Focus Therapeutic Use
- Sponsors Novartis
- 24 Nov 2005 New trial record.